Metformin in polycystic ovary syndrome: systematic review and meta-analysis

By J. Lord, I. Flight, R. Norman. British medical journal, 2003

767 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level (2008, background): “The main use of metformin is in the treatment of type II diabetes and beneficial effects have been observed in the treatment of polycystic ovarian syndrome (PCOS; Lord et al., 2003), nonalcoholic fatty liver disease (NAFLD; Marchesini et al.”
Population-Level Prediction of Type 2 Diabetes From Claims Data and Analysis of Risk Factors (2015, unknown): “The list of medications was based on existing diabetes outcome definitions, 27 and we excluded Metformin from the deﬁnition of diabetes due to its signiﬁcant usage in treatment of polycystic ovarian syndrome 28 and prediabetes.”
How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis (2007, background): “, 2003 (13) Based on 3 new trials, increase in ovulation with metformin plus clomiphene vs.”
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. (2014, unknown): “Metformin has been reported to improve ovulation rates in women with PCOS when given alone or together with CC (1, 282) and has been widely used in women with oligo-or anovulation.”